These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21577136)

  • 1. Routine laboratory monitoring for low-molecular-weight heparin prophylaxis in burns? Not so fast!
    Lundy JB; Lairet K; Chung KK; Renz EM
    J Burn Care Res; 2011; 32(4):e155. PubMed ID: 21577136
    [No Abstract]   [Full Text] [Related]  

  • 2. Enoxaparin and antifactor Xa levels in acute burn patients.
    Lin H; Faraklas I; Cochran A; Saffle J
    J Burn Care Res; 2011; 32(1):1-5. PubMed ID: 21124231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin and antifactor Xa levels in pediatric acute burn patients.
    Brown A; Faraklas I; Ghanem M; Cochran A
    J Burn Care Res; 2013; 34(6):628-32. PubMed ID: 24043233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased enoxaparin dosing is required for obese children.
    Lewis TV; Johnson PN; Nebbia AM; Dunlap M
    Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-duration venous thromboembolism prophylaxis for medical patients.
    Nieto JA; Valle R; Lopez-Saez JB
    Ann Intern Med; 2010 Nov; 153(10):688-9; author reply 689-90. PubMed ID: 21079231
    [No Abstract]   [Full Text] [Related]  

  • 6. Summaries for patients. Safety of surgery during bridging anticoagulation therapy with low-molecular-weight heparin.
    Ann Intern Med; 2007 Feb; 146(3):I35. PubMed ID: 17283344
    [No Abstract]   [Full Text] [Related]  

  • 7. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
    Bickford A; Majercik S; Bledsoe J; Smith K; Johnston R; Dickerson J; White T
    Am J Surg; 2013 Dec; 206(6):847-51, discussion 851-2. PubMed ID: 24070664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-duration venous thromboembolism prophylaxis for medical patients.
    Carson MP; Kuo YH
    Ann Intern Med; 2010 Nov; 153(10):689; author reply 689-90. PubMed ID: 21079233
    [No Abstract]   [Full Text] [Related]  

  • 9. Extended-duration venous thromboembolism prophylaxis for medical patients.
    Dentali F; Gianni M; Squizzato A
    Ann Intern Med; 2010 Nov; 153(10):688; author reply 689-90. PubMed ID: 21079232
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of an enoxaparin dosing calculator using burn size and weight.
    Faraklas I; Ghanem M; Brown A; Cochran A
    J Burn Care Res; 2013; 34(6):621-7. PubMed ID: 24043245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
    Saxer F; Dick W
    Z Orthop Unfall; 2010 Jan; 148(1):26-30. PubMed ID: 20135590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
    Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
    J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin: a review of its use as thromboprophylaxis in acutely ill, nonsurgical patients.
    Siddiqui MA; Wagstaff AJ
    Drugs; 2005; 65(7):1025-36. PubMed ID: 15892594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular-weight heparin administration in patients with end-stage renal disease--a comment.
    Lile J
    Pharmacotherapy; 2001 Aug; 21(8):1017; author reply 1017-9. PubMed ID: 11718492
    [No Abstract]   [Full Text] [Related]  

  • 16. Summaries for patients. Do the benefits of prolonged low-molecular-weight heparin treatment outweigh the harms in hospitalized patients who are bedbound?
    Ann Intern Med; 2010 Jul; 153(1):I-50. PubMed ID: 20621897
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-weight-based enoxaparin dosing subtherapeutic in trauma patients.
    Chapman SA; Irwin ED; Reicks P; Beilman GJ
    J Surg Res; 2016 Mar; 201(1):181-7. PubMed ID: 26850200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.
    Hull RD; Schellong SM; Tapson VF; Monreal M; Samama MM; Nicol P; Vicaut E; Turpie AG; Yusen RD;
    Ann Intern Med; 2010 Jul; 153(1):8-18. PubMed ID: 20621900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing chemoprophylaxis against venous thromboembolism in abdominoplasty patients with the use of preoperative heparin administration.
    Campbell W; Pierson J; Cohen-Shohet R; Mast BA
    Ann Plast Surg; 2014; 72(6):S94-6. PubMed ID: 24691325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of venous thromboembolism using enoxaparin in day surgery: results of the SMART noninterventional study.
    Haas S; Hohmann V; Bramlage P
    Clin Appl Thromb Hemost; 2012 Jun; 18(3):265-71. PubMed ID: 22084412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.